VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KYLE HILL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Veterans VET
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KYLE HILL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Defense DEF
Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Trade (domestic/foreign) TRD
Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
Health Issues HCR
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KYLE HILL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Medicare/Medicaid MMM
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KYLE HILL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Taxation/Internal Revenue Code TAX
Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SWARNA VALLURUPALLI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.